Epoch HealthHigher Mortality Found Among Vaccinated Patients Hospitalized for COVID-19: New Study

Exploring the Paradox: Higher Mortality in Vaccinated COVID-19 Patients Raises Questions About Immune Response Dynamics

A recent study published in Frontiers in Immunology highlights a concerning trend: vaccinated COVID-19 patients hospitalized with acute respiratory failure exhibit a higher mortality rate compared to their unvaccinated counterparts. This counterintuitive finding prompts a deeper examination of vaccine efficacy, immune response mechanisms, and the potential influence of underlying health conditions on patient outcomes.

Key Points:

• A study found that hospitalized COVID-19 patients who were vaccinated had a 70% mortality rate compared to 37% in unvaccinated patients.
• Researchers analyzed data from 152 adults at Ohio State University Hospital, noting that vaccinated patients were generally older and less healthy.
• The study observed that vaccinated patients had lower levels of antibodies compared to unvaccinated patients, challenging the expected correlation between vaccination and antibody-mediated protection.
• Among the 23 vaccinated patients in the study, mortality rates varied with the type and completeness of the vaccine series received.
• Survival rates were notably higher in unvaccinated patients across different age groups, with a significant decrease in survival observed in patients over 80.
• Vaccinated individuals showed an increased average time from initial vaccine dose to hospital admission among those who did not survive, suggesting a potential waning of vaccine-induced immunity over time.
• The study posits that mRNA vaccines might increase COVID-19 spike-specific IgG4 levels without necessarily providing effective protection, referencing a phenomenon termed “immune tolerance.”
• Comparative analyses indicated that unvaccinated patients admitted after vaccine authorization had a higher mortality risk than those admitted before, hinting at the influence of circulating virus variants.
• The findings raise questions about the role of IgG4-related noninfectious diseases, particularly in patients over 50, in the context of COVID-19 vaccine response and mortality.

In a study from 2021, the effectiveness of full vaccination in preventing COVID-19-associated hospitalization among adults aged ≥75 years was 91% for Pfizer-BioNTech, 96% for Moderna, and 85% for Janssen vaccine products. This contrasts with the new study’s findings, highlighting the complexity of vaccine effectiveness.

More in Allergy & Immunology